| 2025/06/20 | 15:45:46 | Medeon approved to release Directors and its representatives from Non-Competition Restrictions at the Annual Shareholders’ Meeting | |
| SEQ_NO |
3 |
Date of announcement |
2025/06/20 |
Time of announcement |
15:45:46 |
| Subject |
Medeon approved to release Directors and its representatives from Non-Competition Restrictions at the Annual Shareholders' Meeting |
| Date of events |
2025/06/20
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2025/06/20
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
CENTER LABORATORIES INC. ; Director
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director
Jien Wei Yeh; Independent Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as Medeon Biodesign, Inc.
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of Medeon Biodesign, Inc.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
Shares represented at the time of voting: 53,776,859 rights
Number of voting rights of shareholders present at the time of voting
Votes in favor 53,093,937 votes?APercentage of the total represented share
present 98.73%
Votes against 131,105 votes?APercentage of the total represented share
present 0.24%
Votes invalid 0 votes?APercentage of the total represented share
present 0.00%
Votes abstained 551,817 votes?APercentage of the total represented share
present 1.02%
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):
Legal Representative of CENTER LABORATORIES INC., Jung Chin Lin; Director
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:
Director, Guangzhou Hybot Technology Co., Ltd.
8.Address of the mainland China enterprise:
Guangzhou Hybot Technology Co., Ltd.?GRoom 201-16, 2nd Floor, Building 3,
Industrial Internet Innovation Center, No. 2-1 Ketai 1st Road, Guangzhou
Private Science and Technology Park, Baiyun District, Guangzhou, China
9.Operations of the mainland China enterprise:
Guangzhou Hybot Technology Co., Ltd.?GSales of New Energy Vehicles
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2025/06/20 | 15:34:06 | Announcement for the material resolutions at the 2025 Annual Shareholders’ Meeting. | |
| SEQ_NO |
2 |
Date of announcement |
2025/06/20 |
Time of announcement |
15:34:06 |
| Subject |
Announcement for the material resolutions at the 2025 Annual Shareholders’ Meeting. |
| Date of events |
2025/06/20
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2025/06/20
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2024 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:
Approval of the amendment to the Articles of Incorporation
4.Important resolutions III.Business report and financial statements:
Ratification of 2024 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:
(1) Approval of the proposal for the private placement to issue
additional common shares
(2) Approval of the release of directors or its representatives from
Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
| 2025/06/20 | 15:26:24 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2025/06/20 |
Time of announcement |
15:26:24 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2025/06/20
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2025/06/20
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
May 2025 May 2024 YoY Change %
—————————————————————————
Sales revenue 35.221 20.691 70.22%
Loss before income tax (62.153) (68.184) 8.85%
Net Loss attributable to
Owners of the parent (59.555) (109.144) 45.43%
EPS (NT$) (0.65) (1.18) 44.92%(‘?l’?)
===========================================================================
(2)Quarterly
Q1 2025 Q1 2024 YoY Change %
—————————————————————————
Sales revenue 101.878 47.141 116.11%
Loss before income tax (190.856) (214.799) 11.15%
Net Loss attributable to
Owners of the parent (177.993) (199.827) 10.93%
EPS (NT$) (1.93) (2.17) 11.06%(‘?l’?)
===========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q2 2024 to Q2 2025)
—————————————————————————
Revenue 347.545
Loss before income tax (834.700)
Net Loss attributable to
Owners of the parent (783.678)
EPS (NT$) (8.50)
===========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
On May 7, 2025, Medeon announced the content of material information press
conference, disclosing the preliminary clinical results for the IDE Study
in evaluating its BPH minimally invasive treatment device Urocross.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
On May 7, 2025, Medeon announced to host the material information press
conference, disclosing the preliminary clinical results for the IDE Study
in evaluating its BPH minimally invasive treatment device Urocross.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for May 2025 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed)
by CPA; it is only for reference by investors.
(2)The information for the latest quarter (Q1 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS,
which have been audited (reviewed) by CPA; it is only for reference
by investors.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q2 2024 to Q1 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA; it is only
for reference by investors. |
|
| 2025/05/23 | 15:48:45 | BOD of Medeon’s major subsidiary PMC re-elected Mr. Yue Teh Jang as the Chairman. | |
| SEQ_NO |
6 |
Date of announcement |
2025/05/23 |
Time of announcement |
15:48:45 |
| Subject |
BOD of Medeon’s major subsidiary PMC re-elected Mr. Yue Teh Jang as the Chairman. |
| Date of events |
2025/05/23
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of the board of directors resolution or date of occurrence of the
change:2025/05/23
2.Position (Please enter chairperson or president/general manager):
Chairperson
3.Name of the previous position holder:Yue Teh Jang
4.Resume of the previous position holder:Chairman, PMC
5.Name of the new position holder:Yue Teh Jang
6.Resume of the new position holder:Chairman, PMC
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’ , ‘job relocation’, ‘severance’, ‘retirement’,
‘death’ or ‘new appointment’):Term expired
8.Reason for the change:Term expired and re-elected
9.Effective date of the new appointment:2025/05/23
10.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2025/05/23 | 15:43:39 | Major Subsidiary PMC Announces Lifting of Non-Compete Restrictions on Directors at 2025 Annual Shareholders’ Meeting. | |
| SEQ_NO |
5 |
Date of announcement |
2025/05/23 |
Time of announcement |
15:43:39 |
| Subject |
Major Subsidiary PMC Announces Lifting of Non-Compete Restrictions on Directors at 2025 Annual Shareholders' Meeting. |
| Date of events |
2025/05/23
|
To which item it meets |
paragraph 21 |
| Statement |
1.Date of the shareholders’ meeting resolution:2025/05/23
2.Name and title of the managerial officer with permission
to engage in competitive conduct:
Medeon Biodesign, Inc.
Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
Legal Representative of Medeon Biodesign, Inc. Albert Weng; Director
Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
3.Items of competitive conduct in which the officer is
permitted to engage:
Invest in or manage other companies with the same or similar scope of
business as PMC
4.Period of permission to engage in the competitive conduct:
During the period of serving as director of PMC
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):
The proposal was resolved as proposed after the chairman inquired of all
attending shareholders.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter ‘N/A’ below):N/A
7.Company name of the mainland China enterprise and the
officer’s position in the enterprise:N/A
8.Address of the mainland China enterprise:N/A
9.Operations of the mainland China enterprise:N/A
10.Impact on the company’s finance and business:N/A
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:N/A
12.Any other matters that need to be specified:None |
|
| 2025/05/23 | 15:36:53 | Announcement of the Election Results for Directors and Supervisor of Major Subsidiary PMC at the 2025 Annual Shareholders’ Meeting. | |
| SEQ_NO |
4 |
Date of announcement |
2025/05/23 |
Time of announcement |
15:36:53 |
| Subject |
Announcement of the Election Results for Directors and Supervisor of Major Subsidiary PMC at the 2025 Annual Shareholders' Meeting. |
| Date of events |
2025/05/23
|
To which item it meets |
paragraph 6 |
| Statement |
1.Date of occurrence of the change:2025/05/23
2.Elected or changed position (Please enter institutional
director, institutional supervisor, independent director,
natural-person director or natural-person supervisor):
institutional director, natural-person supervisor
3.Title and name of the previous position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Albert Weng; Director
(3) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(4) Supervisor: Elisa Huang
4.Resume of the previous position holder:
(1) Yue Teh Jang; Chairman of PMC
(2) Albert Weng; Director of PMC
(3) Jenny Chen; Director of PMC
(4) Supervisor: Elisa Huang; Supervisor of PMC
5.Title and name of the new position holder:
(1) Legal Representative of Medeon Biodesign, Inc. Yue Teh Jang; Chairman
(2) Legal Representative of Medeon Biodesign, Inc. Albert Weng; Director
(3) Legal Representative of Medeon Biodesign, Inc. Jenny Chen; Director
(4) Supervisor: Elisa Huang
6.Resume of the new position holder:
(1) Yue Teh Jang; Chairman of PMC
(2) Albert Weng; Director of PMC
(3) Jenny Chen; Director of PMC
(4) Supervisor: Elisa Huang; Supervisor of PMC
7.Circumstances of change (Please enter ‘resignation’, ‘dismissal’,
‘term expired’, ‘death’ or ‘new appointment’):term expired
8.Reason for the change:Term expired re-elected
9.Number of shares held by the new position holder when elected:
(1) Legal Representative of Medeon Biodesign, Inc.
Yue Teh Jang; 28,761,000 shares
(2) Legal Representative of Medeon Biodesign, Inc.
Albert Weng; 28,761,000 shares
(3) Legal Representative of Medeon Biodesign, Inc.
Jenny Chen; 28,761,000 shares
(4) Supervisor: Elisa Huang; 0 shares
10.Original term (from __________ to __________):2022/05/27~2025/05/26
11.Effective date of the new appointment:2025/05/23
12.Turnover rate of directors of the same term:NA
13.Turnover rate of independent directors of the same term:NA
14.Turnover rate of supervisors of the same term:NA
15.Change in one-third or more of directors (Please enter ‘Yes’ or
‘No’):No
16.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 6
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):None |
|
| 2025/05/23 | 15:15:31 | Announcement for the important resolutions at the 2025 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, PMC | |
| SEQ_NO |
2 |
Date of announcement |
2025/05/23 |
Time of announcement |
15:15:31 |
| Subject |
Announcement for the important resolutions at the 2025 Annual Shareholders’ Meeting on behalf of Medeon’s major subsidiary, PMC |
| Date of events |
2025/05/23
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2025/05/23
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2024 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2024 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:
Election the 4th session of Directors and Supervisor
6.Important resolutions V.Other matters:
Approval for the release of newly elected directors or its representatives
from Non-Competition Restrictions.
7.Any other matters that need to be specified:None |
|
| 2025/05/23 | 15:09:04 | Announcement for the important resolutions at the 2025 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix | |
| SEQ_NO |
1 |
Date of announcement |
2025/05/23 |
Time of announcement |
15:09:04 |
| Subject |
Announcement for the important resolutions at the 2025 Medeologix Annual Shareholders’ Meeting, on behalf of the major subsidiary, Medeologix |
| Date of events |
2025/05/23
|
To which item it meets |
paragraph 18 |
| Statement |
1.Date of the shareholders’ meeting:2025/05/23
2.Important resolutions I.Profit distribution/deficit compensation:
Ratification of 2024 deficit offset proposal
3.Important resolutions II.Amendments of the company charter:None
4.Important resolutions III.Business report and financial statements:
Ratification of 2024 Business Report and Financial Statements
5.Important resolutions IV.Election for directors and supervisors:None
6.Important resolutions V.Other matters:None
7.Any other matters that need to be specified:None |
|
| 2025/05/15 | 15:14:37 | The Company has been required by TPEx to announce the financial data according to the regulations. | |
| SEQ_NO |
1 |
Date of announcement |
2025/05/15 |
Time of announcement |
15:14:37 |
| Subject |
The Company has been required by TPEx to announce the financial data according to the regulations. |
| Date of events |
2025/05/15
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event: 2025/05/15
2.Cause of occurrence:Announced as required by the TPEx
3.Financial and business information:
Unit: (NT$million)
(1) Monthly
April 2025 April 2024 YoY Change %
—————————————————————————
Sales revenue 35.914 20.738 73.18%
Loss before income tax (64.912) (73.120) 11.23%
Net Loss attributable to
Owners of the parent (61.889) (62.427) 0.86
EPS (NT$) (0.67) (0.68) 1.47%(‘?l’?)
===========================================================================
(2)Quarterly
Q1 2025 Q1 2024 YoY Change %
—————————————————————————
Sales revenue 101.878 47.141 116.11%
Loss before income tax (190.856) (214.799) 11.15%
Net Loss attributable to
Owners of the parent (177.993) (199.827) 10.93%
EPS (NT$) (1.93) (2.17) 11.06%(‘?l’?)
===========================================================================
(3)Cumulative for the last four seasons
Latest 4 quarters accumulation
(Q2 2024 to Q2 2025)
—————————————————————————
Revenue 347.545
Loss before income tax (834.700)
Net Loss attributable to
Owners of the parent (783.678)
EPS (NT$) (8.50)
===========================================================================
4.Any material information that needs to be specified
according to Article 4 of Taipei Exchange Procedures
for Verification and Disclosure of Material Information
of Companies with TPEx Listed Securities:
On May 7, 2025, Medeon announced the content of material information press
conference, disclosing the preliminary clinical results for the IDE Study
in evaluating its BPH minimally invasive treatment device Urocross.
5.Any material information in a press conference listed
under Article 11 of Taipei Exchange Procedures for
Verification and Disclosure of Material Information of
Companies with TPEx Listed Securities:
On May 7, 2025, Medeon announced to host the material information press
conference, disclosing the preliminary clinical results for the IDE Study
in evaluating its BPH minimally invasive treatment device Urocross.
6.Any other matters that need to be specified:
(1)The aforementioned financial information for April 2025 and its YOY
comparison consists in the consolidated reviewed amounts prepared by
the Company adopting the IFRS, and has not been audited (reviewed)
by CPA; it is only for reference by investors.
(2)The information for the latest quarter (Q1 2025) refers to single
quarter amounts, not cumulative amounts from the latest financial
reports, and are consolidated amounts prepared under the IFRS,
which have been audited (reviewed) by CPA; it is only for reference
by investors.
(3)The information accumulated over the last 4 quarters consists in the
consolidated amounts from Q2 2024 to Q1 2025 prepared by the Company
adopting the IFRS, and has been audited (reviewed) by CPA; it is only
for reference by investors. |
|
| 2025/05/14 | 23:38:35 | Medeon received the Milestone Abandonment Notice from Terumo | |
| SEQ_NO |
1 |
Date of announcement |
2025/05/14 |
Time of announcement |
23:38:35 |
| Subject |
Medeon received the Milestone Abandonment Notice from Terumo |
| Date of events |
2025/05/14
|
To which item it meets |
paragraph 53 |
| Statement |
1.Date of occurrence of the event:2025/05/14
2.Company name:Medeon Biodesign, Inc.
3.Relationship to the Company (please enter ‘head office’ or
‘subsidiaries’):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
On May 14, 2025, Taipei time, Medeon was notified by Terumo Medical
Corporation (hereinafter referred to as Terumo) that in light of the
pandemic and supply chain challenges, the timeline for launching
Cross-Seal (Large-bore Closure Device) was revised, and has the
potential impact on its original objectives. In accordance of the
Cross-Seal Asset Purchase Agreement and Master Services Agreement,
Terumo proceeded to formally submit the Milestone Abandonment Notice
to Medeon.
Cross-Seal Asset Purchase Agreement is still effective. Both parties
are currently in close communication regarding the subsequent actions
and are actively seeking the most appropriate resolution. It is hoped
that, through continued dialogue, a mutually acceptable and constructive
solution can be reached.
6.Countermeasures:
To publish this announcement.
7.Any other matters that need to be specified(the information
disclosure also meets the requirements of Article 7, subparagraph 9
of the Securities and Exchange Act Enforcement Rules, which brings
forth a significant impact on shareholders rights or the price of
the securities on public companies.):
The development timeline for Cross-Seal is long and entails significant
risks, with no assurance of successful market approval. The expected
milestone-related payments can only be realized upon achievement of the
agreed-upon milestones within the specified timeframe. These factors may
expose the investment to potential risks, and investors are advised to
exercise careful judgment and invest with caution. |
|
